A method and a system for producing a change in a medium. The method places in a vicinity of the medium at least one energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.

Graphene is chemically modified by a process resulting in the introduction of functional groups located only at an edge of the graphene plane. The functionalised graphene finds uses in numerous applications and further chemical synthesis, including a process for coupling an organic or inorganic moiety to the graphene plane via the edge-located functional group. The disclosed products and processes provide highly flexible platforms for the integration of graphene into a variety of applications.

A method and a system for producing a change in a medium disposed in an artificial container. The method places in a vicinity of the medium at least one of a plasmonics agent and an energy modulation agent. The method applies an initiation energy through the artificial container to the medium. The initiation energy interacts with the plasmonics agent or the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the plasmonics agent or the energy modulation agent.

A method and a system for producing a change in a medium disposed in an artificial container. The method places inavicinity of the medium at least one of a plasmonics agent and an energy modulation agent. The method applies an initiation energy through the artificial container to the medium. The initiation energy interacts with the plasmonics agent or the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the plasmonics agent or the energy modulation agent.

In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.

In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.

An upconversion nanoparticle includes at least one host selected from LiYF.sub.4, NaY, NaYF.sub.4, NaGdF.sub.4, and CaF.sub.3, at least one sensitizer selected from Sm.sup.3+, Nd.sup.3+, Dy.sup.3+, Ho.sup.3+, and Yb.sup.3+ doped in the at least one host, and at least one activator selected from Er.sup.3+, Ho.sup.3+, Tm.sup.3+, and Eu.sup.3+ doped in the at least one host. The upconversion nanoparticle is designed using a calculation from first principles to absorb light in the near-infrared wavelength range whose stability is ensured. Further, a hyaluronic acid-upconversion nanoparticle conjugate, in which the upconversion nanoparticle as described above is bonded to hyaluronic acid, is provided to be used in various internal sites with a hyaluronic acid receptor, particularly enables targeting, and increases an internal retention period and biocompatibility thereof.

Disclosed herein are iron oxide nanoparticles prepared through high-temperature thermal decomposition of an Fe.sup.3+ precursor and an M.sup.+ or M.sup.2+ (M=Li, Na, K, Mg, and Ca) precursor in an oxygen atmosphere. The iron oxide nanoparticles are nanoparticles, in which an alkali metal or alkali earth metal is doped into an Fe vacancy site of -Fe.sub.2O.sub.3, and generate explosive heat even in a biocompatible low AC magnetic field. Through both in vitro and in vivo tests, it was proven that cancer cells could be killed by performing low-frequency hyperthermia using the iron oxide nanoparticles set forth above.

The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.

Graphene is chemically modified by a process resulting in the introduction of functional groups located only at an edge of the graphene plane. The functionalized graphene finds uses in numerous applications and further chemical synthesis, including a process for coupling an organic or inorganic moiety to the graphene plane via the edge-located functional group. The disclosed products and processes provide highly flexible platforms for the integration of graphene into a variety of applications.